PCRX
Pacira BioSciences, Inc.
PCRX's fundamentals are strong: its operating margin went from −18% to 4.8% and it turned 23% of its revenue into free cash flow. At 39x earnings, it's trading below its usual 63x. Analysts expect earnings growth, though they disagree widely on how much.
PCRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Strong | |
| Strong |
PCRX's profitability, cash flow and balance sheet are currently healthy. There isn't enough data to rate its revenue.
PCRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $36.46 | — |
| Cheap | 19x | $17.40 | -52% |
| Current | 39x | $36.46 | — |
| Fair | 59x | $55.10 | +51% |
| Expensive | 166x | $156 | +328% |
Historical ranges are pointers, not guarantees.
PCRX's PE is in its fair range at 39x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its cheap range.
PCRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect PCRX's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.23 | +244% |
| Q3 2026 | $0.94 | +92% |
| Q2 2026 | $0.36 | +$3.10 |
| Q1 2026 | $0.13 | +$2.37 |
| Q4 2025 | $0.16 | +$2.31 |
| Q3 2025 | $0.49 | +$2.44 |
| Q2 2025 | -$2.74 | -297% |
| Q1 2025 | -$2.24 | -248% |
| Q4 2024 | -$2.15 | -342% |
PCRX's earnings per share have fallen from their peak: $0.94 over the past year, against $3.91 in mid-2021.
PCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $176.7M | -1.6% |
| Q2 2026 | $192.4M | +6.2% |
| Q1 2026 | $177.4M | +5% |
| Q3 2025 | $179.5M | +6.5% |
| Q2 2025 | $181.1M | +1.7% |
| Q1 2025 | $168.9M | +1.1% |
| Q3 2024 | $168.6M | +2.8% |
| Q2 2024 | $178M | +5% |
PCRX's revenue has picked up after two years of holding roughly level: $177M last quarter, down 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +9.1 points |
| Q2 2026 | 2.2% | -2.5 points |
| Q1 2026 | 3.9% | +2.7 points |
| Q4 2025 | 1.2% | N/A |
| Q3 2025 | 3.5% | +86 points |
| Q2 2025 | 4.7% | -11 points |
| Q1 2025 | 1.2% | -6.7 points |
| Q3 2024 | -83% | -94 points |
PCRX's operating margin was 13% last quarter, up 9.1 points from the same quarter a year ago.
PCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | -18% |
| Q2 2026 | $56.1M | +503% |
| Q1 2026 | $23M | -15% |
| Q4 2025 | $43.5M | +40% |
| Q3 2025 | $57M | +14% |
| Q2 2025 | $9.3M | -82% |
| Q1 2025 | $26.9M | -42% |
| Q4 2024 | $31M | -32% |
PCRX generated $169M in free cash flow over the past year, up 36% from the year before.
PCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +530K shares |
| 1 year | -8.2% | -3.6M shares |
| 3 years | -22% | -11.2M shares |
| 5 years | -10% | -4.6M shares |
| Available history | -1.6% | -683K shares |
PCRX has 41M diluted shares, down 8.2% from a year ago, with $98M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $50M |
| Q4 2025 | $48.2M |
| Q3 2025 | $50M |
| Q4 2024 | — |
| Q3 2024 | — |
PCRX spent $98M buying back its own shares over the past year.
PCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q4 2024 | 57.0x | High |
| Q3 2024 | -22.1x | Net Cash |
| Q2 2024 | -1.5x | Net Cash |
PCRX's net debt is less than a year of its operating earnings (EBITDA), down from 1.7 years a year ago.
PCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.6 | Overbought |
| Stochastic | 98.3 | Overbought |
PCRX's weekly RSI is 78 (overbought) and its Stochastic is 98 (overbought).
PCRX PE vs Healthcare Sector
| Metric | PCRX | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 26x | 50% above |
| PE % | 37 | 29 | 8 pts above |
PCRX is trading at 39x earnings, a 50% premium to the Healthcare sector's median of 26x.
PCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.6 | 8.5% above |
| 20 week MA | $28.6 | 27% above |
| 50 week MA | $25.4 | 44% above |
| 100 week MA | $24.7 | 48% above |
| 200 week MA | $27.3 | 33% above |
PCRX has climbed back above all five of its weekly moving averages, and it's now 33% above its 200-week average.
PCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.6 | $59.2 | +33% |
| 2021 | $59.2 | $61.7 | +4.1% |
| 2022 | $61.7 | $39.7 | -36% |
| 2023 | $39.7 | $33.7 | -15% |
| 2024 | $33.7 | $19.7 | -42% |
| 2025 | $19.7 | $26.5 | +35% |
| 2026 YTD | $26.5 | $36.5 | +38% |
PCRX is up 38% so far in 2026, after finishing lower in three of the previous six years.